Viewing Study NCT07016334


Ignite Creation Date: 2025-12-25 @ 2:30 AM
Ignite Modification Date: 2025-12-30 @ 2:17 PM
Study NCT ID: NCT07016334
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-11
First Post: 2025-05-21
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: We Analyse Metabolites in Dried Blood Spots From Newborns That Later in Life Developed an Eating Disorder.
Sponsor: Karolinska Institutet
Organization:

Study Overview

Official Title: The Role of Metabolic, Immune, and Neurotrophic Markers in the Etiology of Eating Disorders Using Neonatal Bloodspots
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Anorexia nervosa (AN) and bulimia nervosa (BN) are serious eating disorders (EDs) with significant morbidity and mortality. Genetic studies have shown associations between EDs and metabolic traits, and longitudinal studies indicate distinct weight trajectories in children who later develop AN or BN, suggesting early involvement of metabolic factors. Biological studies also reveal differences in immune and neurotrophic markers in individuals with EDs compared to controls. Intriguingly, metabolites measured in neonatal blood could serve as very early markers of ED risk, unconfounded by state or scar factors related to prolonged starvation.

Here the investigators propose to comprehensively analyze neonatal biomarkers (metabolic, immune, and neurotrophic), epidemiological factors, and genetics to understand ED risk and develop risk prediction models
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: